The U.S. Trustee, the bankruptcy arm of the Justice Department, will appoint one or more committees to represent the interests of creditors and stockholders in working with the company to develop a plan of reorganization to get out of debt.
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).
Soliris was considered as a treatment option due to its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection. As a result, Alexion's German subsidiary provided an unspecified number of Soliris doses at no charge to physicians who requested it.